Coloplast H1 2021/22 STRIVE25 Roadshow Presentation

Coloplast Group's H1 2021/22 investor roadshow presentation highlighting the STRIVE25 sustainable growth strategy across Ostomy Care, Continence Care, Wound & Skin Care, and Interventional Urology divisions. Reported 7% organic revenue growth and 31% EBIT margin, with Atos Medical contributing 6 percentage points to growth following acquisition.